| Active substance | sacituzumab govitecan |
| Holder | Gilead Sciences Belgium BV |
| Status | closed |
| Indication |
as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 10/01/2025 |